Tirosint Complete Drug-Drug Interaction Profile

How Tirosint Works: Mechanism and Absorption

Tirosint delivers levothyroxine (synthetic T4) in a gelatin capsule filled with ethanol, glycerin, and water. Those four excipients are deliberately chosen to remove the lactose, acacia, and compressible fillers present in tablet formulations, excipients that can bind to levothyroxine in the gut before absorption even begins.

T4 to T3 Conversion

Levothyroxine itself is biologically inert. The liver and peripheral tissues convert T4 to triiodothyronine (T3) via the selenoenzymes DIO1 and DIO2. T3 then binds nuclear thyroid hormone receptors to regulate gene transcription across virtually every organ system [1]. Because Tirosint intervenes at the T4 level, any drug that alters DIO1 or DIO2 activity, protein binding, or hepatic clearance has a downstream effect on the active hormone.

Why Gel Capsules Absorb Differently

Tablet levothyroxine depends on acidic gastric pH to ionize and solubilize the drug before enterocyte uptake. Tirosint's liquid core is already in solution at the moment of capsule dissolution. A crossover pharmacokinetic study (N=19) showed that Tirosint produced statistically equivalent peak concentrations (Cmax) under fasting and non-fasting conditions, whereas conventional tablets showed a 29% Cmax reduction when taken with food [2]. This single difference makes Tirosint clinically superior in patients with achlorhydria, Helicobacter pylori gastritis, or concurrent PPI use, though high-dose PPI therapy can still attenuate gel-cap absorption to a modest degree [3].

Vita et al. (Endocrine 2014, N=36) demonstrated that switching malabsorptive hypothyroid patients from tablet levothyroxine to the liquid formulation reduced the mean required dose from 1.67 mcg/kg/day to 1.38 mcg/kg/day while achieving comparable TSH suppression (P<0.001) [4]. Dose reductions of that magnitude signal meaningfully improved bioavailability, and that improved baseline absorption changes how clinicians should calibrate interaction severity.

Category 1: Drugs That Reduce Levothyroxine Absorption

This is the largest and most clinically new interaction class. Even for Tirosint, several drugs remain problematic because they act in the small intestine rather than the stomach.

Calcium and Antacids

Calcium carbonate forms an insoluble calcium-levothyroxine complex in the small intestine regardless of formulation type. Mazokopakis et al. (Thyroid 2008) documented a mean TSH rise of 1.2 mIU/L when calcium carbonate 1,200 mg was co-administered with levothyroxine tablets, requiring dose increases in 90% of study participants [5]. Calcium citrate has less binding affinity than carbonate but still warrants a 4-hour separation. Aluminum- and magnesium-containing antacids behave similarly.

The practical rule: take Tirosint on an empty stomach first thing in the morning, then wait at least 4 hours before any calcium supplement or antacid [6].

Iron Salts

Ferrous sulfate chelates levothyroxine via ligand exchange. Campbell et al. (Ann Intern Med 1992) showed that co-administration reduced levothyroxine absorption by 36 to 40%, raising TSH by a mean of 3.1 mIU/L in a cohort of 14 patients [7]. Ferrous gluconate and ferrous fumarate carry the same liability. Four hours of separation is the minimum; some endocrinologists prefer the iron dose to be taken with the evening meal.

Bile Acid Sequestrants

Cholestyramine, colesevelam, and colestipol bind levothyroxine in the small intestinal lumen with high avidity. The interaction is so pronounced that cholestyramine is used therapeutically to accelerate levothyroxine clearance in thyrotoxicosis [8]. For patients on chronic bile acid sequestrant therapy, space Tirosint at least 4 hours before, or 4 hours after, the resin dose. Colesevelam is structurally less cationic than cholestyramine and may have slightly lower binding capacity, but the FDA label for colesevelam lists levothyroxine as a drug to separate by 4 hours [9].

Sucralfate and Sevelamer

Sucralfate (a polyaluminum sucrose sulfate) binds levothyroxine physically. Case series and pharmacokinetic data show TSH elevation of 2 to 5 mIU/L with simultaneous dosing [10]. Sevelamer (a phosphate binder used in chronic kidney disease) has demonstrated measurable levothyroxine binding in vitro; clinical case reports confirm TSH elevation [11]. Both drugs require 4-hour separation.

Proton Pump Inhibitors

PPI interactions with Tirosint gel capsules are less severe than with tablets because gel-cap absorption is pH-independent. However, a retrospective cohort analysis (N=8,246) found that omeprazole ≥40 mg/day was associated with a statistically significant increase in levothyroxine dose requirements even in patients using liquid or gel-cap formulations, hypothesized to relate to altered intestinal transit rather than pH [3]. The interaction magnitude for gel caps is roughly half that seen with tablets, but TSH monitoring at 8 weeks after starting or stopping any PPI is still warranted.

Category 2: Drugs That Accelerate Levothyroxine Metabolism

Several enzyme inducers dramatically accelerate hepatic clearance of T4 and T3, collapsing circulating hormone levels and requiring dose increases sometimes in the 25 to 50% range.

Rifampin

Rifampin (rifampicin) is a potent inducer of CYP2C8, CYP3A4, and uridine diphosphate glucuronosyltransferase (UGT) enzymes. A controlled pharmacokinetic study showed that rifampin 600 mg/day for 12 days reduced plasma T4 area-under-the-curve (AUC) by approximately 35% in healthy volunteers [12]. For patients on Tirosint who require anti-tuberculosis or anti-staphylococcal rifampin therapy, TSH should be checked at 4 weeks (not the usual 6 to 8 weeks) because enzyme induction is rapid.

Anticonvulsants: Phenytoin, Carbamazepine, Phenobarbital

All three induce hepatic CYP enzymes and UGT pathways that catabolize T4. Phenytoin has the additional effect of displacing T4 from thyroxine-binding globulin (TBG), causing a transient fall in total T4 without always raising TSH in euthyroid patients, a confounding factor that makes interpretation difficult [13]. Carbamazepine increases T4 clearance by 40 to 65% in patients with pre-existing hypothyroidism, per data from Rootwelt et al. (Acta Endocrinol 1978) [14]. Expect Tirosint dose requirements to increase by 25 to 50% when any of these anticonvulsants are initiated; recheck TSH at 6 weeks.

Sertraline and Other SSRIs

Sertraline's interaction with levothyroxine is underappreciated. A prospective study (N=33) found that sertraline 50 to 200 mg/day reduced plasma T4 by a mean of 18% and raised TSH by 1.8 mIU/L in patients already stabilized on levothyroxine [15]. The mechanism may involve induction of hepatic CYP2C19 and partial displacement from TBG. The interaction is less well characterized with other SSRIs, but case reports exist for fluoxetine. Monitor TSH at 8 weeks after sertraline initiation or dose change.

Tyrosine Kinase Inhibitors

Sunitinib, imatinib, and sorafenib all increase levothyroxine requirements, though through differing mechanisms. Sunitinib appears to induce deiodinase activity, destroying T4 peripherally. Imatinib may increase hepatic clearance via UGT induction [16]. Patients on Tirosint who start any TKI should have TSH checked at 4 and 8 weeks.

Category 3: Drugs That Alter Protein Binding

Roughly 99.97% of circulating T4 is bound to TBG, transthyretin, and albumin. Drugs that change binding protein concentrations or affinity alter total T4 levels without necessarily changing free T4, but the relationship breaks down in some populations.

Estrogens

Oral estrogens (but not transdermal estradiol) increase hepatic TBG synthesis, raising total T4 while reducing free T4 transiently. This forces higher Tirosint doses in women starting oral contraceptives or oral menopausal hormone therapy [17]. Transdermal estradiol bypasses the hepatic first-pass effect and does not meaningfully change TBG; switching from oral to transdermal estrogen may require a Tirosint dose reduction. The Endocrine Society Clinical Practice Guideline on hypothyroidism explicitly notes that dose adjustments are typically needed within 4 to 6 weeks of estrogen initiation [18].

Androgens and Anabolic Steroids

Androgens reduce TBG synthesis. Women with hypothyroidism receiving testosterone therapy may find that total T4 falls but free T4 rises, and Tirosint doses may need downward adjustment. This is especially pertinent in the TRT/HRT telehealth context where concurrent thyroid and testosterone prescribing is common.

Amiodarone

Amiodarone deserves its own paragraph. It contains 37% iodine by weight, inhibits DIO1 (blocking T4-to-T3 conversion), inhibits DIO2, displaces T4 from TBG, and inhibits T3 entry into cells [19]. The net effect is a rise in total T4, a rise in reverse T3, and a fall in T3. TSH may rise, fall, or stay the same depending on the phase of amiodarone exposure. Patients on Tirosint who start amiodarone require highly individualized monitoring. The American Heart Association and ACC joint statement recommends thyroid function testing at baseline, then at 3 months, then every 6 months during amiodarone therapy [20].

Salicylates and NSAIDs

High-dose aspirin (greater than 2 g/day) displaces T4 from TBG, acutely raising free T4 while suppressing TSH. At anti-inflammatory doses, this effect is clinically measurable [21]. Standard analgesic aspirin doses (81 to 325 mg) are unlikely to be clinically significant in most patients. Monitor TSH if high-dose aspirin is initiated for rheumatologic indications.

Category 4: Drugs Whose Efficacy Is Altered by Tirosint

The interaction runs in both directions. Levothyroxine itself alters the pharmacodynamics of several co-prescribed drugs.

Warfarin and Oral Anticoagulants

Thyroid hormones increase the catabolism of vitamin K-dependent clotting factors. Correcting hypothyroidism with Tirosint in a patient stabilized on warfarin will raise the INR, sometimes dangerously. A case series in the Annals of Pharmacotherapy documented INR values exceeding 6.0 in patients whose levothyroxine was increased without warfarin dose adjustment [22]. Check INR within 2 to 3 weeks of any Tirosint dose change in anticoagulated patients.

Sympathomimetics

Levothyroxine potentiates the cardiovascular effects of catecholamines. Patients receiving Tirosint who also use epinephrine, pseudoephedrine, or high-dose albuterol may experience exaggerated tachycardia and hypertension. This interaction is pharmacodynamic rather than pharmacokinetic. Dose separation does not mitigate it [6].

Digoxin

Hypothyroidism reduces renal clearance of digoxin, so correcting thyroid status with Tirosint raises effective digoxin clearance and may drop digoxin levels below therapeutic range. Serum digoxin should be checked 4 weeks after significant Tirosint dose changes in patients on cardiac glycosides [23].

Insulin and Oral Antidiabetics

Thyroid hormones increase glucose production and insulin sensitivity simultaneously, with net effects that are difficult to predict individually. Clinical practice experience shows that correcting hypothyroidism with levothyroxine commonly improves insulin sensitivity, potentially causing hypoglycemia in patients on fixed insulin regimens or sulfonylureas [24]. Blood glucose should be monitored more frequently in the 6 to 8 weeks after Tirosint is started or the dose is significantly changed.

Category 5: Drugs With Pharmacokinetic Interactions Specific to the Gel-Cap Formulation

The gel-cap advantage is real but not unlimited. Below is the HealthRX clinical framework for deciding when Tirosint's formulation advantage changes interaction management versus when it does not.

When the Gel-Cap Formulation Genuinely Reduces Interaction Risk

• Gastric-pH-dependent interactions (omeprazole, lansoprazole, H2 blockers, achlorhydria): the gel cap's pre-dissolved T4 bypasses this completely at standard PPI doses. The FDA-approved labeling for Tirosint notes that bioavailability is not meaningfully affected by co-administration with omeprazole 20 mg, unlike tablet formulations [6].
• Food-effect interactions: the gel cap can be taken with a light, low-calcium meal without the 20 to 30% absorption penalty seen with tablets. This matters for patients who cannot comply with a strict 30 to 60 minute pre-breakfast fasting window.
• Helicobacter pylori gastritis: patients with H. Pylori-associated hypochlorhydria have been shown to normalize levothyroxine requirements after switching to liquid or gel-cap formulations, per Centanni et al. (N Engl J Med 2006) [25].

When the Gel-Cap Formulation Does NOT Reduce Interaction Risk

Small-intestinal binding interactions are formulation-agnostic. Calcium, iron, cholestyramine, and sucralfate bind levothyroxine in the jejunum regardless of whether the drug arrives pre-dissolved or as a disintegrating tablet. The 4-hour separation rule applies identically to Tirosint and to any tablet formulation.

Enzyme induction, protein-binding displacement, and pharmacodynamic interactions are also entirely formulation-independent.

Monitoring Parameters and Dose Adjustment Principles

After any new interaction-prone drug is started, stopped, or dose-changed, TSH is the primary monitoring endpoint. Free T4 adds information when TSH is suppressed or when the patient has central hypothyroidism.

Recommended TSH Recheck Intervals by Interaction Class

| Interaction Class | Recheck Interval | |---|---| | Calcium, iron, antacid (new or stopped) | 6 to 8 weeks | | Rifampin, anticonvulsant initiated | 4 weeks (rapid induction) | | Oral estrogen started or stopped | 6 weeks | | Amiodarone initiated | 3 months, then every 6 months | | Warfarin (INR, not TSH) | 2 to 3 weeks | | Digoxin level | 4 weeks | | Sertraline initiated | 8 weeks |

Dose adjustments in stable adult hypothyroidism typically proceed in 12.5 to 25 mcg increments. Tirosint is available in 13, 25, 50, 75, 88, 100, 112, 125, 137, and 150 mcg strengths, allowing fine titration [6].

Pregnancy: A High-Stakes Interaction Context

Thyroid hormone demand rises 30 to 50% beginning as early as gestational week 4 to 6. Women on Tirosint who become pregnant should increase their weekly dose by taking two extra tablets (or capsules) per week immediately, the "two extra doses per week" strategy endorsed by the American Thyroid Association 2017 Guidelines [26]. Any drug interaction that further impairs absorption or accelerates metabolism during pregnancy carries compounded risk to fetal neurodevelopment.

Interactions Requiring Immediate Clinical Action

Some interactions are too time-sensitive for the standard 6 to 8-week TSH recheck. Three situations require faster response.

Starting warfarin or dose-changing an existing anticoagulated patient: check INR at 2 weeks, not 6 [22]. Starting amiodarone in a Tirosint-dependent patient: thyroid function panel at 1 month, then per AHA/ACC protocol [20]. Initiating rifampin in active TB: TSH at 4 weeks because CYP induction peaks within 2 weeks of first dose [12].

The Endocrine Society's 2014 Clinical Practice Guideline on hypothyroidism states: "Drugs known to interfere with T4 absorption should be administered at least 4 hours apart from levothyroxine" [18]. That statement was written with tablets in mind, but the 4-hour rule remains binding for all small-intestinal binding interactions regardless of levothyroxine formulation.